['muscular dystrophy, duchenne']
['edasalonexent', 'placebo']

        Inclusion Criteria:

          -  Written informed consent from parent or legal guardian prior to participation and, for
             patients who are 7 years of age, written assent from patient

          -  Diagnosis of DMD based on a clinical phenotype with increased serum CK and the
             presence of a mutation in the dystrophin gene known to be associated with a DMD
             phenotype

          -  Ability to walk independently (assistive devices are permitted)

          -  Adequate immunization for influenza and varicella

        Exclusion Criteria:

          -  Use of corticosteroids within prior 6 months of treatment initiation or planning to
             initiate steroid therapy within the next 6 months

          -  Other prior or ongoing significant medical conditions

          -  Exposure to another investigational drug (such as eteplirsen or idebenone) within 28
             days prior to start of study treatment or ongoing participation in any other
             therapeutic clinical trial

               -  Note: There are separate criteria for patients who participated in Part A versus
                  newly enrolling patients. New patients must meet all of the Part A entry criteria
                  to participate in Part B.

        Patients who participated in Part A must meet the following criteria to participate in Part
        B:

          -  Completed Part A

          -  Continue to meet all of the Part A entry criteria, including an absence of safety
             concerns (however, patients may be ≥8 years of age)

        There are no entry criteria for Part C; all patients who complete Part B will automatically
        continue in Part C
      